[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100645164":3},{"organization":4,"armGroups":7,"interventions":30,"overallOfficials":35,"centralContacts":46,"locations":56,"responsibleParty":71,"collaborators":73,"id":76,"slug":77,"hasResults":78,"nctId":79,"briefTitle":80,"officialTitle":80,"acronym":81,"eligibilityCriteria":82,"healthyVolunteers":83,"sex":84,"minAge":85,"maxAge":86,"enrollmentInfo":87,"targetDuration":35,"studyType":90,"phases":91,"briefSummary":93,"conditions":94,"keywords":35,"overallStatus":103,"whyStopped":35,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":108,"completionDateStruct":110,"leadSponsor":112,"locationsCount":113},{"fullName":5,"class":6},"University of Copenhagen","OTHER",[8,14,20,25],{"label":9,"type":10,"description":11,"interventionNames":12},"Isotonic saline","PLACEBO_COMPARATOR","Saltwater infusion in a peripheral vein",[13],"Other: isotonic saline infusion",{"label":15,"type":16,"description":17,"interventionNames":18},"GIP(1-42)","ACTIVE_COMPARATOR","Infusion of the native hormone GIP(1-42) in a peripheral vein",[19],"Other: Infusion of GIP(1-42)",{"label":21,"type":16,"description":22,"interventionNames":23},"GLP-2(1-33)","Infusion of the native hormone GLP-2(1-33) in a peripheral vein",[24],"Other: Infusion of GLP-2(1-33)",{"label":26,"type":16,"description":27,"interventionNames":28},"Pramlintide","Infusion of pramlintide (amylin analogue) in a peripheral vein",[29],"Other: Infusion of pramlintide",[31,36,40,43],{"type":6,"name":32,"description":33,"armGroupLabels":34,"otherNames":35},"isotonic saline infusion","Placebo infusion for comparison of active hormone",[9],null,{"type":6,"name":37,"description":38,"armGroupLabels":39,"otherNames":35},"Infusion of GIP(1-42)","Study tool",[15],{"type":6,"name":41,"description":38,"armGroupLabels":42,"otherNames":35},"Infusion of GLP-2(1-33)",[21],{"type":6,"name":44,"description":38,"armGroupLabels":45,"otherNames":35},"Infusion of pramlintide",[26],[47,52],{"name":48,"role":49,"phone":50,"phoneExt":35,"email":51},"Lærke S Gasbjerg, MD, PhD","CONTACT","+4525346894","lsg@sund.ku.dk",{"name":53,"role":49,"phone":54,"phoneExt":35,"email":55},"Mette G Thomsen, Cand.Scient","+4560624598","mette.grodal@sund.ku.dk",[57],{"facility":58,"status":35,"city":59,"state":35,"zip":35,"country":60,"countryCode":61,"cosmosGeoPoint":62,"geoPoint":67,"contacts":68},"Rigshospitalet","Copenhagen","Denmark","DK",{"type":63,"coordinates":64},"Point",[65,66],12.56553,55.67594,{"lat":66,"lon":65},[69],{"name":70,"role":49,"phone":54,"phoneExt":35,"email":55},"Mette G Thomsen, Cand.scient",{"type":72,"investigatorFullName":35,"investigatorTitle":35,"investigatorAffiliation":35,"oldNameTitle":35,"oldOrganization":35},"SPONSOR",[74],{"name":75,"class":6},"Rigshospitalet, Denmark","100645164","postprandial-regulation-of-bone-perfusion-in-healthy-individuals-100645164",false,"NCT07679516","Postprandial Regulation of Bone Perfusion in Healthy Individuals","GA-27","Inclusion Criteria:\n\n1. Age 25-50 years.\n2. BMI between 18.5-30 kg\u002Fm2.\n3. Normal gait.\n4. Premenopausal (if female).\n5. Informed consent.\n\nExclusion Criteria:\n\n1. Bone disease incl. confirmed osteopenia.\n2. Fracture within the last 6 months at the time of inclusion.\n3. Amputation or congenital defect of extremities.\n4. HbA1c\\>41.9 mmol\u002Fmol and\u002For diagnosed type 1 or type 2 diabetes.\n5. Any ongoing or prior medication that the investigator evaluates could interfere with the endpoints of the study (e.g. glucocorticoids or other medications that may compromise bone health).\n6. Pregnancy or breastfeeding (or plans thereof within the study duration).\n7. Not using effective hormonal contraceptives or an intra uterine device within study duration (e.g. oral contraceptives, transdermal patch, vaginal ring, Depo-Provera injections, Nexplanon implant).\n8. Ongoing or prior alcohol abuse (defined per ICD-10 classification for alcohol dependence syndrome, F10.21) or daily alcohol intake\n9. Use of any illicit substance or narcotics within three months of inclusion, including within study duration.\n10. Any physical or psychological condition that the investigator evaluates would interfere with trial participation.\n11. Recent (three months prior to inclusion), ongoing or planned weight loss within study duration (weight loss defined as exceeding -5% bodyweight, or intentional hypocaloric dieting)",true,"ALL","25 Years","50 Years",{"count":88,"type":89},15,"ESTIMATED","INTERVENTIONAL",[92],"NA","The goal of this clinical trial is to learn whether certain natural hormones - Glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-2, (GLP-2), and amylin - affect blood flow to the bones.",[95,96,97,98,99,100,101,102],"Healthy Adult Participants","Bone Physiology","Bone Blood Flow Regulation","GLP-2","GIP","Amylin","Peptide Hormones","Gut Hormones","NOT_YET_RECRUITING","2026-06-25",{"date":106,"type":107},"2026-07-01","ACTUAL",{"date":109,"type":89},"2026-07-19",{"date":111,"type":89},"2028-05",{"name":5,"class":6},1]